Sugi Predict

Sugi Predict / Compounds / SCHEMBL1553339

SCHEMBL1553339

SCHEMBL1553339

CCOC(=O)/C(C#N)=C(/C)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.50
▸ CYP19A1 P11511 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ LMNA P02545 3/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ MEN1 O00255 5/20 0.46
▸ KMT2A Q03164 5/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ GAA P10253 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ XBP1 P17861 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12446816 1.00 MAPT (0.50) MAPTCYP19A1ALDH1A1LMNAMAPK1
SCHEMBL1553340 1.00 MAPT (0.50) MAPTCYP19A1ALDH1A1LMNAMAPK1
SCHEMBL11138252 0.92 MAPT (0.46) MAPTCYP19A1ALDH1A1LMNASMN1; SMN2
SCHEMBL11138250 0.92 MAPT (0.46) MAPTCYP19A1ALDH1A1LMNASMN1; SMN2
SCHEMBL1554070 0.88 DHODH (0.44) MAPTCYP19A1ALDH1A1LMNAMAPK1
SCHEMBL1554071 0.88 DHODH (0.44) MAPTCYP19A1ALDH1A1LMNAMAPK1
SCHEMBL11669329 0.87 AKR1C3 (0.49) MAPTCYP19A1ALDH1A1LMNAMAPK1
Etocrylene SCHEMBL1768864 0.86 ALDH1A1 (0.62) MAPTCYP19A1ALDH1A1LMNAMAPK1
SCHEMBL8076180 0.86 MAPT (0.56) MAPTALDH1A1LMNAMAPK1SMN1; SMN2
Etocrylene SCHEMBL39390 0.86 ALDH1A1 (0.62) MAPTCYP19A1ALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108484849-B Ionic polymer antistatic agent and preparation method thereof 中红普林医疗用品股份有限公司 2021-11-16 — — CN claimed
US-9466827-B2 Secondary battery NEC CORPORATION (JP) 2016-10-11 — — US claimed
US-20260043010-A1 ENONE REDUCTASES CODEXIS, INC. (US) 2026-02-12 — — US disclosed
US-12371674-B2 Enone reductases CODEXIS, INC. (US) 2025-07-29 — — US disclosed
CN-118221635-A Aryl thiophene compound and preparation method and application thereof 沈阳药科大学 2024-06-21 — — CN disclosed
CN-108484849-B Ionic polymer antistatic agent and preparation method thereof 中红普林医疗用品股份有限公司 2021-11-16 — — CN disclosed
US-20210324344-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2021-10-21 — — US disclosed
US-10995321-B2 Enone reductases CODEXIS, INC. (US) 2021-05-04 — — US disclosed
EP-3172272-B1 MODIFIED HETEROPHASIC POLYOLEFIN COMPOSITION MILLIKEN & CO (US) 2020-11-25 — — EP disclosed
US-20200040311-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2020-02-06 — — US disclosed
US-20180312815-A1 ENONE REDUCTASES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2018-11-01 — — US disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 — — US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 — — WO disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 — — EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 — — US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 — — WO disclosed
EP-1121094-A1 UV PROTECTION COMPOSITIONS The Procter & Gamble Company (US) 2001-08-08 — — EP disclosed
US-6224854-B1 UV protection compositions THE PROCTER & GAMBLE COMPANY 2001-05-01 — — US disclosed
WO-2000023044-A1 UV PROTECTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-04-27 — — WO disclosed
US-4524206-A TREATMENT OF NERVOUS SYSTEM DISORDER; DRUG OVERDOSE REVERSAL MEAD JOHNSON & COMPANY (US) 1985-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312815-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B MAPT 4492/4885CYP19A1 612/4885ALDH1A1 1267/4885
US-10995321-B2 Enone reductases ENO1, DCXR, RRM2B MAPT 4492/4885CYP19A1 612/4885ALDH1A1 1267/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE MAPT 1176/4885CYP19A1 3845/4885ALDH1A1 1591/4885
US-20200040311-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B MAPT 4492/4885CYP19A1 612/4885ALDH1A1 1267/4885
US-12371674-B2 Enone reductases ENO1, DCXR, RRM2B MAPT 4492/4885CYP19A1 612/4885ALDH1A1 1267/4885
US-20260043010-A1 ENONE REDUCTASES DCXR, ENY2, UPF1 MAPT 4465/4885CYP19A1 193/4885ALDH1A1 2992/4885
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPT 2978/4885CYP19A1 512/4885ALDH1A1 247/4885
US-20210324344-A1 ENONE REDUCTASES ENO1, DCXR, RRM2B MAPT 4492/4885CYP19A1 612/4885ALDH1A1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.